Title
Category
Credits
Event date
Cost
  • CMHC
  • ACPE Pharmacy
  • AMA PRA Category 1 Credit™
  • ANCC
  • CDE
  • Participation
$0.00
Patients with diabetes and PAD, particularly those with concomitant polyvascular disease, are at a greater risk for future adverse cardiovascular and limb events.
  • CMHC
  • ACPE Pharmacy
  • AMA PRA Category 1 Credit™
  • ANCC
  • CDE
  • Participation
$0.00
Lowering LDL-C effectively and safely is crucial in preventing ASCVD events. Even with the advances in LDL-C-lowering therapy, there is considerable residual risk due to suboptimal adherence, clinical efficacy, or clinical inertia, which increases the chances of serious adverse CV events. Several new and emerging agents may help address these gaps in the near future, and clinicians need to be aware of these new approaches and their potential role in the treatment of high-risk patients with elevated LDL-C.
  • CMHC
  • TME
  • ACPE Pharmacy
  • AMA PRA Category 1 Credit™
  • ANCC
  • Participation
$0.00
Patient with ILDs, especially those with a progressive fibrosis phenotype, maybe at a greater risk for having worse outcomes with COVID-19, including during and post-COVID-19 infection. However, the management of patients with PF-ILDs and COVID-19 is not clear, including the potential management of COVID-19 related lung injury and fibrosis, as well as the overall management of ILDs in the COVID-19 era. During this webcast, experts will discuss these gaps and the implications of COVID-19 in the management of patients with ILDs and PF-ILD.
  • CMHC
  • ACPE Pharmacy
  • AMA PRA Category 1 Credit™
  • ANCC
  • CDE
  • Participation
$0.00
The 2020 Annual CMHC On Demand - Evolving Paradigms in Cardiometabolic Care: Disparities & Advancements will translate the latest cutting-edge medical research into practical, clinical strategies for preventing, delaying, diagnosing, treating, and managing the whole spectrum of cardiometabolic disorders. The goal is to provide the medical community with evidence-based interventions that they can apply immediately in clinical practice to improve health outcomes and quality of life for the growing numbers of patients at increased cardiometabolic risk.
  • CMHC
  • ACPE Pharmacy
  • AMA PRA Category 1 Credit™
  • ANCC
  • CDE
  • Participation
$0.00
Familial hypercholesterolemia (FH) remains underdiagnosed and undertreated, which increases ASCVD risk, morbidity and mortality in HF patients.In addition, the relatively low insurance approvals for newer LDL-C lowering agents, even for high-risk FH patients, has limited patients’ access to these necessary therapies, increasing their risk for morbidity and mortality. These challenges in diagnosis and treatment are even more apparent in racial and ethnic minorities.
  • CMHC
  • ACPE Pharmacy
  • AMA PRA Category 1 Credit™
  • ANCC
  • CDE
  • Participation
$0.00
Diabetic kidney disease (DKD) is one of the most common complications of diabetes, affecting up to 50% of persons with diabetes, and leading to increased morbidity and mortality. Despite optimized glycemic control and renin-angiotensin-aldosterone system (RAAS) inhibitor therapy, many patients with DKD progress to kidney failure. Recent advances in the understanding of disease pathophysiology have opened up new avenues of treatment, including mineralocorticoid receptor antagonism, which have the potential to improve outcomes for patients with DKD.
  • CMHC
  • ACPE Pharmacy
  • AMA PRA Category 1 Credit™
  • ANCC
  • CDE
  • Participation
$0.00
Diabetes increases the risk of cardiovascular and thrombotic adverse events in patients with CAD compared to patients with these conditions and no concomitant diabetes.  As such, current antiplatelet therapy to prevent adverse events in these high-risk patients may not be adequate, and several recently-completed and ongoing clinical trials are evaluating the efficacy and safety of additional approaches, including the use of more aggressive and specific antithrombotic agents in this setting. 
  • CMHC
  • ACPE Pharmacy
  • AMA PRA Category 1 Credit™
  • ANCC
  • CDE
  • Participation
$0.00
Hyperkalemia is a serious condition associated with increased risk of mortality and is frequently prevalent and recurrent in patients who suffer from heart failure (HF), chronic kidney disease (CKD), and/or hypertension (HTN). Comorbid illnesses and use of medicines that are important for kidney and cardiac outcomes but elevate potassium levels can also increase the chronic risk for hyperkalemia.
  • CMHC
  • ACPE Pharmacy
  • AMA PRA Category 1 Credit™
  • ANCC
  • CDE
  • Participation
$0.00
Current evidence supports post-prandial glucose (PPG) control as an important strategy to consider in the comprehensive management plan of individuals with diabetes.  However, managing PPG remains one of the most challenging aspects of diabetes care.
  • CMHC
  • ACPE Pharmacy
  • AMA PRA Category 1 Credit™
  • ANCC
  • CDE
  • Participation
$0.00
While a substantial body of research demonstrates the need to address the global epidemic of metabolic syndrome, and the constellation of associated cardiometabolic risk factors simultaneously, the majority of them are still treated as separate entities.The engaging and interactive session recordings from this Masterclass cover experts across specialties on the current state of affairs and advances in cardiometabolic disease including team based-care, telemedicine, cardio-renal risk reduction, obesity management, and much more.

Pages